Recent 8-K filings for JUNS
Highest-materiality recent filing
Jupiter Neurosciences shareholders approve 4x increase in authorized shares to 500M and new equity plan
- Authorized common stock increased from 125M to 500M shares via amendment approved by 20.2M votes for, 4.5M against.
- 2025 Equity Incentive Plan approved, authorizing 5,250,000 shares for future equity awards.
-
Jupiter Neurosciences signs $3.33M non-binding term sheet for exclusive U.S. rights to ALA-002 MDMA
Upfront consideration $3.33M ($1.5M cash + $1.83M JUNS stock with 120-day lock-up); $600K escrow deposited.
-
Jupiter Neurosciences receives Nasdaq deficiency notices for bid price and market value
Two Nasdaq deficiency notices received Feb 26, 2026: bid price <$1.00 for 30 consecutive days.
-
Authorized common stock increased from 125M to 500M shares via amendment approved by 20.2M votes for, 4.5M against.
-
Jupiter Neurosciences secures up to $20M flexible financing from Yorkville; $4M funded at signing
Initial $4M pre-paid advance funded via convertible note with $1.50 fixed conversion price and 7% OID.
-
Jupiter Neurosciences receives Nasdaq delisting notice for bid price non-compliance
Nasdaq notified JUNS on Mar 21, 2025 that bid price closed below $1.00 for 30 consecutive business days through Mar 20, 2025.
-
One-time payment of $2,300,000 to Dominant Treasure for services to accelerate product development and distribution in Southeast Asia.
-
Jupiter Neurosciences closes IPO on Nasdaq, raises $11M gross from 2.75M shares at $4.00
IPO of 2,750,000 common shares priced at $4.00/sh for gross proceeds of $11M.
Materiality & sentiment trend
Max materiality 0.80 · Median 0.55 · Most common event other_material